Healthcare >> CEO Interviews >> January 10, 2001
DAVID C. U'PRICHARD joined 3-Dimensional Pharmaceuticals (3DP) in
September 1999 as Chief Executive Officer and member of the Board of
Directors. Dr. U'Prichard led 3DP as an evolving R&D pipeline company to
its successful IPO in August 2000, and over $50M in committed revenue in
2001/2002 through substantial pipeline and technology collaborations,
including Johnson & Johnson (oral thrombin inhibitors and DiscoverWorks
small molecule lead generation platform) and Bristol-Myers Squibb
(DioscoverWorks platform). Dr. U'Prichard was formerly President,
Research and Development, SmithKline Beecham Pharmaceuticals, which he
joined in 1997. While at SmithKline Beecham, he instituted a major
reorganization of the 5,000-member research and development function to
rebalance the focus toward the commercial needs of the company. Amongst
many activities, he oversaw the entry of 10 compounds into clinical
development, and progressed the clinical development to NDA filing of
Avandia, the blockbuster diabetes drug. Prior to joining SmithKline
Beecham, Dr. U'Prichard served as EVP and International Research
Director of Zeneca, with ultimate responsibility for a research staff of
1,000 based in the UK, US and France. He joined ICI/Zeneca (now
Astra/Zeneca) as Vice President, Biomedical Research in 1986 and assumed
global responsibilities for Zeneca's discovery research after the Zeneca
demerger in 1993. Dr. U'Prichard, as VP R&D, was instrumental in the
successful launch of Nova Pharmaceuticals in 1983, following his post-
doctoral fellowship at Johns Hopkins University and academic career as a
tenured Associate Professor of Pharmacology and Neurobiology at
Northwestern University (1978-1983). He has also held faculty
appointments at Johns Hopkins University (1975-1978; 1983-86),
University of Maryland, and the University of Pennsylvania, and is an
Honorary Professor at the University of Glasgow, Scotland. Dr.
U'Prichard received a BSc in Pharmacology with first-class honors from
the University of Glasgow in 1970, and a PhD in Pharmacology from the
University of Kansas in 1975. He is author of more than 100 primary and
review publications and was a founding co-editor of Molecular
Neurobiology, co-editor of Epinephrine in the Central Nervous System,
and has served as a member of numerous editorial boards. Dr. U'Prichard
serves on the Boards of Directors of Lynx Therapeutics, Inc., a public
company, and Predict, Inc., RiboTargets plc, and GeneMatrix, Inc., all
private companies, and he is on the Board of the Pennsylvania
Biotechnology Association Profile
3DP?
Dr. U'Prichard: 3DP was founded in 1993. The founder was
Dr. Ray Salemme, who is currently President and Chief
